Allergan�s $AGN planned $640 million acquisition of Vitae Pharmaceuticals, which was likely to close this quarter, apparently has hit a roadblock after analysts reported that one of its two main pipeline candidates VTP-38543, failed to show a treatment benefit in a Phase 2 clinical trial in atopic dermatitis. It now only has one medium-term candidate in development, psoriasis med VTP-43742. Earlier in September, $AGN announced its acquisition plans at a premium of 160%, at that moment.